- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00372736
AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors
A Phase I Study of AEG35156 Given as a 2 Hour Intravenous Infusion in Combination With Docetaxel in Patients With Solid Tumours
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. AEG35156 may help docetaxel work better by making tumor cells more sensitive to the drug.
PURPOSE: This phase I trial is studying the side effects and best dose of AEG35156 when given together with docetaxel in treating patients with locally advanced, metastatic, or recurrent solid tumors.
Study Overview
Status
Detailed Description
OBJECTIVES:
Primary
- Determine the maximum tolerated dose and define a recommended phase II dose of AEG35156 in combination with docetaxel in patients with locally advanced, metastatic, or recurrent solid tumors.
Secondary
- Determine the qualitative and quantitative toxicities of AEG35156 in combination with docetaxel given and define the duration and reversibility of those toxicities.
- Determine the pharmacokinetic profile of this regimen.
- Assess, preliminarily, the antitumor activity of this regimen in these patients.
- Assess the pharmacodynamic effects of AEG35156 on X-linked inhibitor of apoptosis levels and apoptosis in peripheral blood mononuclear cells and in tumor tissue of these patients.
- Evaluate M30/M65 cytokeratin 18 level (a marker of apoptosis/necrosis of epithelial tumors) in serum of these patients.
OUTLINE: This is a multicenter, open-label, dose-escalation study of AEG35156.
Patients receive AEG35156 IV over 2 hours on days -1, 0, 1, 8, and 15 during course 1 and on days 1, 8, and 15 of all subsequent courses. Patients also receive docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of AEG35156 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which ≥ 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Additional patients receive AEG35156 at the recommended phase II dose (RPTD).
Blood is drawn periodically for pharmacokinetic and pharmacodynamic studies. Samples are examined by flow cytometry, immunoenzyme methods, and reverse transcriptase-polymerase chain reaction for biological markers. Tumor tissue (archival and fresh) is collected from patients treated at the RPTD and examined by immunohistochemical methods and biological marker analysis.
After completion of study treatment, all patients are followed at 4 weeks. Patients with response or stable disease ongoing are followed every 3 months thereafter until relapse/progression. Patients with protocol-related toxicity also followed q 3 months until resolution to ≤ grade 2.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BCCA - Vancouver Cancer Centre
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Univ. Health Network-Princess Margaret Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1S6
- McGill University - Dept. Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
DISEASE CHARACTERISTICS:
Histologically confirmed solid tumor
- Locally advanced, metastatic, or recurrent disease that is refractory to standard curative therapy or for which no curative therapy exists
- Clinically and/or radiologically documented disease
- Treatment with single-agent docetaxel is a reasonable treatment option
No newly diagnosed CNS metastases
- Previously treated and stable (≥ 6 months) intracranial disease allowed
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy ≥ 12 weeks
- Absolute granulocyte count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- PT or INR and PTT normal
- Creatinine normal
- Bilirubin normal
- AST and ALT ≤ 1.5 times upper limit of normal (ULN)
- Gamma-glutamyl transferase ≤ 3 times ULN
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
No underlying serious illness or medical condition that might be aggravated by treatment or might interfere with study treatment, including, but not limited to, the following:
- Serious uncontrolled infection
- Significant cardiac dysfunction
- Significant neurological disorder that would impair the ability to obtain informed consent
- No known bleeding disorders
- No prior serious allergic reaction to taxane (paclitaxel or docetaxel)
- No pre-existing peripheral neuropathy ≥ grade 2
PRIOR CONCURRENT THERAPY:
- More than 4 weeks since prior chemotherapy and recovered
- At least 2 weeks since prior hormonal therapy or immunotherapy
At least 4 weeks since prior external-beam radiotherapy to < 30% of marrow-bearing areas
- Low-dose, nonmyelosuppressive radiotherapy allowed
- At least 2 weeks since prior surgery and recovered
- More than 4 weeks since prior investigational agents or new anticancer therapy
- No prior nephrectomy
- No other concurrent chemotherapy
No concurrent radiotherapy
- Small-volume, non-myelosuppressive palliative radiotherapy allowed
- No other concurrent experimental drugs or anticancer therapy
No concurrent therapeutic dose anticoagulant therapy
- Non-therapeutic dose anticoagulant therapy (i.e., 1 mg daily oral warfarin) allowed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose of AEG35156 in combination with docetaxel
Time Frame: 2-3 years
|
Doses of AEG35156 escalated as shown in protocol section 4.3 in patient cohorts given a fixed dose of docetaxel.
MTD defined as that dose level at which ≥ 2/6 patients experienced DLT (as defined in protocol section 4.6)
|
2-3 years
|
Recommended phase II dose
Time Frame: 2-3 years
|
RPTD for AEG35156 defined as one dose lower than MTD
|
2-3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicities
Time Frame: Every 3 weeks
|
Toxicities evaluated according to NCI CTCAE v3.0
|
Every 3 weeks
|
Pharmacokinetic profile
Time Frame: Each cycle
|
Venous blood samples for determination of AEG35156 concentration obtained on all patients during cycle 1 and 2 as per protocol section 17.2
|
Each cycle
|
Antitumor activity
Time Frame: Every 6 weeks
|
All patients with measurable disease at baseline evaluated for response using RECIST criteria as described in protocol section 10.0
|
Every 6 weeks
|
Pharmacodynamic effects of AEG35156 on X-linked inhibitor of apoptosis levels and apoptosis in peripheral blood mononuclear cells and tumor tissue
Time Frame: Each cycle
|
Venous blood samples collected for PD studies as described in protocol Section 17.0.
Fresh tissue biopsies also collected in patients entered at the RPTD.
|
Each cycle
|
M30/M65 cytokeratin 18 level
Time Frame: Each cycle
|
Venous blood samples collected for determination of M30/M65 cytokeratin 18 and nucleosomal DNA as described in protocol section 17.0
|
Each cycle
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Gerald Batist, MD, McGill Cancer Centre at McGill University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- I166B
- CAN-NCIC-IND166B (Other Identifier: PDQ)
- CDR0000486837 (Other Identifier: PDQ)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unspecified Adult Solid Tumor, Protocol Specific
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingCollection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid TumorsUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Kantonsspital GraubuendenUnknownUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificSwitzerland
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Vanderbilt UniversityNational Cancer Institute (NCI)TerminatedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedSirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By SurgeryUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyWithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | Hematopoietic/Lymphoid CancerUnited States
-
University of Texas Southwestern Medical CenterRecruitingUnspecified Adult Solid Tumor, Protocol SpecificUnited States
Clinical Trials on AEG35156
-
Aegera TherapeuticsTerminatedCarcinoma, Non-Small-Cell LungUnited States
-
Aegera TherapeuticsTerminatedHuman Mammary CarcinomaUnited States
-
Aegera TherapeuticsTerminated
-
Aegera TherapeuticsTerminatedLeukemiaUnited States, Canada, Germany
-
Aegera TherapeuticsTerminatedCarcinoma | PancreasUnited States
-
Aegera TherapeuticsThe Leukemia and Lymphoma SocietyTerminatedLymphoma, B-Cell | Leukemia, Lymphocytic, Chronic, B-CellCanada, United States
-
NCIC Clinical Trials GroupCompletedUnspecified Adult Solid Tumor, Protocol SpecificCanada
-
Aegera TherapeuticsChinese University of Hong KongCompletedAdvanced Hepatocellular CarcinomaChina